SkinBioTherapeutics (SBTX) Competitors GBX 14 -0.25 (-1.73%) As of 11:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock SBTX vs. CIR, BVXP, 4BB, TILS, VSN, SCLP, MPH, OBI, ORPH, and HEMOShould you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), Ondine Biomedical (OBI), Open Orphan (ORPH), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry. SkinBioTherapeutics vs. Its Competitors Circassia Group Bioventix 4basebio Tiziana Life Sciences Verseon Scancell Mereo BioPharma Group plc (MPH.L) Ondine Biomedical Open Orphan Hemogenyx Pharmaceuticals SkinBioTherapeutics (LON:SBTX) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Is SBTX or CIR more profitable? Circassia Group has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -237.95%. Circassia Group's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SkinBioTherapeutics-237.95% -115.86% -61.18% Circassia Group N/A N/A N/A Which has preferable earnings and valuation, SBTX or CIR? Circassia Group has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkinBioTherapeutics£2.68M13.53-£3.71M-£0.01-1,120.24Circassia Group£27.90M0.00N/A£0.01N/A Do institutionals and insiders have more ownership in SBTX or CIR? 3.4% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer SBTX or CIR? In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score. Company Overall Sentiment SkinBioTherapeutics Neutral Circassia Group Neutral SummaryCircassia Group beats SkinBioTherapeutics on 6 of the 8 factors compared between the two stocks. Get SkinBioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£36.24M£222.61M£6.04B£2.59BDividend YieldN/A3.81%5.73%5.32%P/E Ratio-1,120.2498.9685.144,390.72Price / Sales13.535,693.53590.92101,116.96Price / Cash9.0013.1925.7727.90Price / Book8.34106.1312.668.01Net Income-£3.71M-£90.99M£3.32B£5.89B7 Day Performance-5.06%-0.41%0.44%0.11%1 Month Performance-14.75%4.10%9.35%1.93%1 Year Performance2.40%736.03%79.07%142.77% SkinBioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSkinBioTherapeuticsN/AGBX 14-1.7%N/A+14.2%£36.24M£2.68M-1,120.2411CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,425flatN/A-39.6%£126.70M£13.66M1,637.19124BB4basebio1.4697 of 5 starsGBX 720-7.1%GBX 1,600+122.2%-46.0%£120.01M£1.78M-727.27101Positive NewsTILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60M-3.5911VSNVerseonN/AN/AN/AN/A£112.24MN/A-5.17N/AGap UpSCLPScancellN/AGBX 10+2.6%N/A-25.8%£101.18M£4.71M-793.6551Gap DownHigh Trading VolumeMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownOBIOndine BiomedicalN/AC$13.50-1.8%N/A+103.8%C$71.28MC$2.05M-192.86N/AORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179HEMOHemogenyx PharmaceuticalsN/AGBX 1,140-3.2%N/A+84,580.5%£63.13MN/A-493.6814 Related Companies and Tools Related Companies Circassia Group Alternatives Bioventix Alternatives 4basebio Alternatives Tiziana Life Sciences Alternatives Verseon Alternatives Scancell Alternatives Mereo BioPharma Group plc (MPH.L) Alternatives Ondine Biomedical Alternatives Open Orphan Alternatives Hemogenyx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:SBTX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SkinBioTherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share SkinBioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
